Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

“…The number of branch points in PV interneuron axons from cuprizone-treated mice was significantly decreased compared to control mice (<i>t test; n = 10/9 cells per group, *p < 0.05</i>). …”

List of DEGs from neuronal cell analysis. by Sara Cuvertino (18892069)

“…We also identify hundreds of differentially expressed genes (DEGs) in iPSCs, NPs and CNs in KS1. In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. …”

List of DEGs from iPSC analysis. by Sara Cuvertino (18892069)

“…We also identify hundreds of differentially expressed genes (DEGs) in iPSCs, NPs and CNs in KS1. In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. …”

The importance of entry criteria from the point of view of the SD method ‐ combinations D1 –D10. by Roman Vavrek (13200141)

The importance of entry criteria from the point of view of the SD method ‐ combinations B1 –B5. by Roman Vavrek (13200141)

The importance of entry criteria from the point of view of the SD method ‐ combinations C1 –C10. by Roman Vavrek (13200141)

Means with standard errors across time points for the outcome of mental health knowledge. by Ana Beato (20489933)

Point load strength apparatus: (a) before modification; (b) after modification. by Hong Zhang (25820)

Subjects:

Effect of 1.25(OH)₂D₃ treatment on proteinuria at different time points after the induction of glomerulonephritis. by Jian-feng Li (8667645)

Subjects:

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

The trends of gene expression in the metabolism of triglycerides in liver tissue. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

The trends in the expression of inflammation-related genes in liver tissue. by Xueqin lu (22250795)

Subjects: